Diagnostic value of prostate imaging - reporting and data system (PI-RADS) version 2 in the Chinese population: a correlation study with magnetic resonance imaging (MRI)/ultrasound (US) fusion targeted biopsy

Abstract

Objective: To evaluate the diagnosticvalue of Prostate Imaging – Reporting andData System (PI-RADS) version 2 in MRIprostate in a Chinese cohort.Patients and Methods: From July 2015to July 2016, 94 Chinese men with ele-vated serum prostate-specific antigen(PSA) of 4–20 ng/mL underwent pre-biopsy multiparametric MRI prostatewith a 1.5T MRI scanner. A panel of 3genitourinary radiologists assignedregions of interests (ROIs) according tothe PI-RADS v2. Those having PI-RADSGrade 2–5 lesion(s) underwent MRI/USfusion targeted biopsy using the Arte-misTMfusion platform.Results: A total of 132 PI-RADS 2–5lesions were detected in 81 patients(mean 1.71.0 lesions per patient). Can-cer detection rates (CDRs) for PI-RADS2, 3, 4 and 5 lesions were 0% (0/44),9.8% (5/51), 34.5% (10/29) and 50.0%(4/8) respectively. For PI-RADS 3–5lesions, 34.1% (30/88) and 65.9% (58/88)were located at the transition andperipheral zones respectively, with nodifference in CDRs at the two sites (30%vs 17.2%, p = 0.18). CDR of clinicallysignificant cancers was signi ficantlyhigher for PI-RADS 4–5 lesions com-pared with PI-RADS 3 lesions (35.1% vs7.8%, p = 0.002).Conclusion: PI-RADS v2 has good corre-lation with biopsy outcomes and can beused as risk-strati fication tool for selectingpatients for targeted biopsy.